https://websites4-live-prod.ysmdevs.com/lab/mishra/news-rss/?orgId=121184&title=Latest+News A selection of the latest research, academic, and other newsworthy developments at Mishra Lab en-us Copyright 2026 Yale School of Medicine Thu, 14 May 2026 19:06:35 Z https://websites4-live-prod.ysmdevs.com/lab/mishra/news-article/poststroke-seizures-new-study-suggests-first-line-treatment-options/ https://websites4-live-prod.ysmdevs.com/lab/mishra/news-article/poststroke-seizures-new-study-suggests-first-line-treatment-options/ A Yale-led comprehensive network meta-analysis identifies lamotrigine and levetiracetam as reasonable first-choice antiseizure medications for preventing poststroke seizures. Fri, 31 Jan 2025 05:00:00 Z https://youtu.be/UwY4qsvnWAE?si=GnCAuPeRkrWyTx1y https://youtu.be/UwY4qsvnWAE?si=GnCAuPeRkrWyTx1y Presented by Assistant Professor of Neurology Nishant Mishra, MD, PhD, this webinar focuses on post-stroke epilepsy and how it can severely impact patients' lives, and provides an update on current research initiatives. Tue, 30 Apr 2024 16:00:00 Z https://www.springermedicine.com/stroke/non-epileptic-seizure/poststroke-seizures-mortality-poor-outcome/26102894 https://www.springermedicine.com/stroke/non-epileptic-seizure/poststroke-seizures-mortality-poor-outcome/26102894 medwireNews: Patients with a history of stroke have a significantly increased risk for mortality, poor functional outcomes, and severe disability if they have poststroke seizures (PSS), a systematic review and meta-analysis shows. “The findings highlight that PSSs are a public health concern and warrant significant research efforts to prevent poststroke epileptogenesis,” say the researchers in JAMA Neurology. Nishant Mishra (Yale University, New Haven, Connecticut, USA) and colleagues analyzed 71 observational, mainly retrospective (66%), studies that were carried out between 1951 and 2023 to compare outcomes for 20,110 stroke patients with PSS and 1,166,085 without PSS. Follow-up ranged from hospital discharge to 26 years. “We suggest that within-study comparisons should be valid if follow- up was the same for patients with and without PSS, but absolute values are not readily interpretable,” say the researchers. Sun, 29 Oct 2023 04:00:00 Z https://www.medicalnewstoday.com/articles/could-transcranial-stimulation-reduce-brain-damage-after-a-stroke https://www.medicalnewstoday.com/articles/could-transcranial-stimulation-reduce-brain-damage-after-a-stroke Dr. Mishra cautioned that “whereas I find the hypothesis underlying this intervention promising, it is currently not ready for use in routine clinical practice.” However, he also noted that “eagerly awaits the intervention’s safety and efficacy data from future larger clinical trials using a study design acceptable to our regulatory body.” “We will be able to offer cathodal transcranial direct current stimulation to ischemic stroke patients currently ineligible for thrombolytic and/or endovascular therapy,” Dr. Mishra explained, as long as “future clinical trials demonstrate that the cathodal transcranial direct current stimulation is safe and efficacious in humans and the U.S. FDA clears this intervention.” Source: https://www.medicalnewstoday.com/articles/could-transcranial-stimulation-reduce-brain-damage-after-a-stroke#An-alternative-treatment-with-potential] Wed, 28 Jun 2023 04:00:00 Z